Raymond James Financial Inc. Acquires Shares of 204,249 Moderna, Inc. (NASDAQ:MRNA)

Raymond James Financial Inc. acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, Holdings Channel.com reports. The fund acquired 204,249 shares of the company’s stock, valued at approximately $8,493,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MRNA. State Street Corp lifted its holdings in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after acquiring an additional 178,115 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Finally, Leerink Partners reduced their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $59.00.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $32.66 on Friday. The firm has a market cap of $12.60 billion, a PE ratio of -3.52 and a beta of 1.86. The firm’s 50 day simple moving average is $34.91 and its 200-day simple moving average is $45.86. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.